



**We Promote Human Health
from Prevention to Cure**

CEO Message



CEO & President of SK bioscience
Jaeyong Ahn

“
From prevention to cure,
SK bioscience is dedicated to shaping
a healthier future for humanity
”

SK bioscience is opening a new chapter toward the global market with the launch of the “SKBS 3.0” era at the Global R&PD Center—Korea’s largest vaccine-specialized research facility that seamlessly integrates processes from basic research to process development.

Building on leading R&D capabilities and state-of-the-art manufacturing facilities, SK bioscience has been at the forefront of Korea’s vaccine industry. Through both the in-house development and contract manufacturing of COVID-19 vaccines, we have demonstrated globally recognized expertise.

Our strong global network—spanning international organizations, research institutions, and industry partners in the vaccine sector—serves as a key driver of sustainable growth. It also enables us to create both Economic Value (EV) and Social Value (SV) simultaneously.

SK bioscience will continue to take the lead in safeguarding global health by expanding our proprietary vaccine portfolio, advancing our R&D and manufacturing infrastructure, and actively pursuing new opportunities in emerging biopharmaceutical areas, alongside securing global manufacturing hubs.

Driven by the passion and dedication of all our employees, we will continue striving to ensure that the hope we build together reaches people around the world.

History

2025

- Obtained U.S. IND for 21-valent pneumococcal vaccine
- Completed Global R&PD Center
- Completed L HOUSE expansion for pneumococcal vaccine commercial production
- Advanced Ebola vaccine collaboration with MSD-Hilleman
- Launched government-funded universal vaccine project
- Filed for global clinical trials and obtained IND approval in Korea for SKYVaricella (2-dose)
- Developed injectable rotavirus vaccine (CDC)

2026

- Initiated global Phase 1/2 trial for universal COVID-19 vaccine (CEPI, IPD)
- In-licensed RSV preventive antibody technology (GF MRI)
- Secured HaDEA-funded patch-based influenza vaccine project (IDT, Vaxxas consortium)
- Advanced next-generation Ebola vaccine development and manufacturing (MSD, Hilleman, IDT)

2022

SKBS 3.0
Next Generation

2024

- Acquired controlling stake in IDT Biologika, a Germany-based vaccine CDMO
- Expanded Sanofi partnership for next-generation PCV
- Initiated global Phase 3 trial for 21-valent PCV
- Invested in ‘Sunflower’, ‘Fina biosolutions’
- Obtained WHO PQ for SKYTyphoid
- Earned Innovative Growth Company designation

2023

- Achieved Phase 2 success for 21-valent PCV (with Sanofi)
- Signed Glocalization* MOU (Thailand GPO, Serbia Government)
* Global + Localization

2022

- Launched SKYCovione, Korea’s first domestically developed COVID-19 vaccine
- Obtained WHO PQ for SKYTyphoid

2018

SKBS 2.0
Quantum Jump

2021

- Listed on KOSPI
- Obtained EU GMP for COVID-19 vaccine manufacturing

2020

- Signed COVID-19 vaccine CDMO agreements (AstraZeneca, Novavax)

2019

- Obtained WHO PQ for SKYCellflu QIV/TIV
- Obtained WHO PQ for SKYVaricella

2018

- Established SK bioscience
- Launched SKYVaricellae

2017

- Launched SKYZoster

2016

- Launched SKYCellflu QIV (World’s first cell culture 4-valent influenza vaccine)

2015

- Launched SKYCellflu (Korea’s first cell culture influenza vaccine)

2014

- Obtained KGMP for L HOUSE
- Signed pneumococcal vaccine collaboration with Sanofi

2013

- Achieved LEED Gold for L HOUSE

2012

- Completed L HOUSE

2005

- Established vaccine R&D center

2001

- Acquired Dongshin Pharmaceutical

2001

SKBS 1.0
Key Growth

At a Glance



Employees (As of Dec. 2025)

1,129



Revenue (As of Dec. 2025)

KRW 651.4 billion



IDT Biologika

SK bioscience USA



Global R&PD Center

38, YeongudANJI-ro, Yeonsu-gu, Incheon, Korea



L HOUSE (Vaccine Manufacturing Plant)

150, Saneopdanji-gil, Pungsan-eup, Andong, Gyeongsangbuk-do, Korea



IDT Biologika

Dessau-Rosslau Am Pharmapark 06861 Dessau-Rosslau, Germany

SK bioscience's Growth Strategy 3.0

MISSION

We Promote Human Health, from Prevention to Cure

VISION

Global Innovative Partner of Vaccine and Biotech



Expansion of Portfolio

- 21-valent and next-generation pneumococcal vaccines
- Pan-sarbecovirus vaccine
- Injectable rotavirus vaccine
- Next-generation Ebola vaccine
- Patch-based influenza vaccine




Strengthening Manufacturing / R&D Infrastructure

- Establishment of the Global R&PD Center
- Expansion of L HOUSE
- AI-driven yield improvement at L HOUSE
- Securing cGMP standards



Execution of SKYShield

- Vaccine development and production localization based on public-private partnerships



Next Pandemic Preparedness

- **Two-track strategy**
- Development capability: Securing new pandemic platforms such as mRNA
- Manufacturing capability: Expanding production facilities and strengthening track record



Expansion of New Bio Business

- Expansion of CDMO business leveraging IDT's manufacturing infrastructure
- Specification of expansion targets based on mRNA platform
- Development of RSV preventive antibody therapeutics

Global Partnership / M&A, JV / Management Infra

Research and Development



Global R&PD* Center

State-of-the-art R&PD center covering the entire R&D process from research to commercial-scale production

* Research & Process Development



Pilot Plant


- A small-scale pilot facility built to test new processes or products prior to full-scale implementation
- Designed to cGMP standards for use in new vaccine development and CDMO projects



R&D Center

- Process development across diverse platforms, including microbial and mammalian cell systems
- mRNA technology research

Platform Technologies



** Virus-Like Particle

Portfolio

Creating Economic Value (EV) and Social Value (SV) through in-house R&D and global partnerships

Funded Public Health Programs

- COVID-19 vaccine (SKYCovione) (GF, CEPI)
- Typhoid vaccine with IVI¹⁾ (GF)
- RSV²⁾ preventive monoclonal antibody (Right Fund)
- IDT, Vaxxas consortium patch-based influenza vaccine (HaDEA)
- Pan-sarbecovirus vaccine (CEPI/GF)
- mRNA vaccines for Japanese encephalitis vaccine and Lassa (CEPI)
- Avian influenza vaccine project (KDCA)
- Vaxxas-partnered typhoid patch vaccine (Welcome Trust sub awardee)
- Vaxxas-partnered mRNA vaccines for Japanese encephalitis (CEPI sub awardee)
- Minibinder intranasal spray for COVID-19 (GF)
- mRNA vaccines for COVID-19 (GF)

In-house Program

- Cell culture influenza vaccine (SKYCellflu)
- Varicella vaccine (SKYVaricella)
- Zoster vaccine (SKYZoster)
- 13-valent pneumococcal vaccine
- 21-valent/Next-generation pneumococcal vaccines (with Sanofi)
- Low-cost HPV vaccine with Sunflower
- Adjuvanted influenza vaccine
- Oncolytic virus, Obesity Vaccines, etc.

CMO/CDMO

- MSD next generation Ebola vaccine³⁾
- Dengue vaccine
- CGT
- Oncology virus
- Botulinum toxin

1) IVI: International Vaccine Institute 2) RSV: Respiratory Syncytial Virus 3) MSD signed in May 2023 and development work for the next generation Ebola vaccine is being performed at Hileman Lab



R&D personnel (As of Dec. 2025)

325



R&D investment

KRW 155.8B




Area

30,413.8m²

Pipeline

※ Pipeline Highlights



1) Gates Medical Research Institute 2) International Vaccine Institute 3) Gates Foundation 4) Centers for Disease Control 5) Coalition for Epidemic Preparedness Innovations
6) Institute for Protein Design 7) Korea Disease Control and Prevention Agency 8) European Health and Digital Executive Agency
*Prequalified by the WHO PQ

Product

SKYCellflu quadrivalent

World's first developed cell-cultured quadrivalent influenza vaccine



Active Ingredient Cell-cultured surface antigen influenza vaccine
| Purified inactivated influenza virus surface antigen (Two Type A antigens, two Type B antigens)

Indications For the prevention of influenza caused by influenza A and B viruses contained in the vaccine in individuals aged 6 months and older, including children, adolescents, and adults

SKYCellflu trivalent

Korea's first domestically developed cell-cultured trivalent influenza vaccine



Active Ingredient Cell-cultured surface antigen influenza vaccine
| Purified inactivated influenza virus surface antigen (Two Type A antigens, one Type B antigen)

Indications For the prevention of influenza caused by influenza A and B viruses contained in the vaccine in individuals aged 6 months and older, including children, adolescents, and adults

SKYZoster

Korea's first domestically developed herpes zoster vaccine



Active Ingredient Live zoster virus vaccine
| Live attenuated herpes zoster virus (Oka/SK)

Indications Prevention of herpes zoster in individuals aged 50 years and older

SKYVaricella

Korea's second domestically developed varicella vaccine



Active Ingredient Live varicella virus vaccine
| Live attenuated varicella-zoster virus (Oka/SK)

Indications For the prevention of varicella (chickenpox) in children aged 12 months to 12 years

SKYTyphoid (Export)

Korea's first domestically developed typhoid



Active Ingredient Typhoid Vi Polysaccharide Conjugated to Diphtheria Toxoid vaccine
| Typhoid Vi Polysaccharide Conjugated to Diphtheria Toxoid

Indications Active immunization for the prevention of typhoid fever caused by Salmonella Typhi in age of ≥ 6 months and ≤ 45 years

SKYCovion

Korea's first domestically developed COVID-19 vaccine



Active Ingredient SARS-CoV-2 surface antigen vaccine (genetically recombined)
| SARS-CoV-2 spike protein RBD antigen (genetically recombined) (Host 1: CHO- K1 (HD-BIOP3), Vector 1: M-2560, Host 2: E.coli (BL21), Vector 2: pET296(+))

Indications For the prevention of COVID-19 caused by the SARS-CoV-2 virus in individuals aged 18 years and older

Manufacturing



L HOUSE

A world-class vaccine plant producing a wide catalog of vaccines

AREA	PRODUCTION	ANIMAL LABS	OFFICE
62,626 m ² + 99,130 m ² (Industrial Complex 2)	32,410 m ² • Filling (pre-filled syringes, vials, freeze-dried products) • DS (10 suites for bacterial and viral vaccines) • Packaging, QA/QC, logistics, facilities	1,573 m ²	4,183 m ²

GMP CERTIFICATIONS

Ministry of Food and Drug Safety

EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

World Health Organization

REPUBLIC OF TÜRKİYE
MINISTRY OF HEALTH


МИНИСТЕРСТВО
ЗДРАВООХРАНЕНИЯ
РОССИЙСКОЙ ФЕДЕРАЦИИ

MHRA

Technology and Competitiveness

SINGLE USE SYSTEM	FLEXIBILITY	FUTURE EXTENSION PLAN
<ul style="list-style-type: none"> • Shorter design stage • Faster process development and optimum scale-up • Reduced initial cost • Minimized inspection of cleaning and sterilization (Reduced spending of time and effort; no need to halt operations) 	<ul style="list-style-type: none"> • Experience with developing various platforms • Flexibility in commercial production • Modular system (Independent operation of individual suites possible) 	<ul style="list-style-type: none"> • Wide range of platforms and improved quality assurance • Dedicated extension area designed for rapid capacity expansion to meet future production demand

Drug Substance Manufacturing


















Drug Product Manufacturing





IDT Biologika

German company, ranked among the world's top 10 vaccine CDMOs, acquired by SK bioscience in October 2024

<p>FOUNDED 1921</p> 	<p>LOCATION</p> <ul style="list-style-type: none"> • Dessau-Roßlau, Germany (HQ & End-to-end manufacturing facility) • Magdeburg, Germany (Process development center) 	<p>TOTAL AREA 1,360,000 m²</p> 				
<p>KEY FINANCIALS (2025 REVENUE €289.7M)</p> <table border="0"> <tr> <td data-bbox="118 1612 419 1784">  <p>Vaccines 55.7%</p> </td> <td data-bbox="428 1612 730 1784">  <p>CGT 12.6%</p> </td> <td data-bbox="739 1612 1041 1784">  <p>DP F&F 29.6%</p> </td> <td data-bbox="1050 1612 1351 1784">  <p>Other 2.1%</p> </td> </tr> </table>			 <p>Vaccines 55.7%</p>	 <p>CGT 12.6%</p>	 <p>DP F&F 29.6%</p>	 <p>Other 2.1%</p>
 <p>Vaccines 55.7%</p>	 <p>CGT 12.6%</p>	 <p>DP F&F 29.6%</p>	 <p>Other 2.1%</p>			


Facts and Figures

<p>WORLDWIDE SUPPLY for the global biopharmaceutical industry and governments</p> 	<p>MORE THAN 100 YEARS of expertise in development and manufacturing vaccines</p> 	<p>MULTIPLE CDMO LEADERSHIP AWARDS won over the past 10 years</p> 
<p>A TRUSTED PARTNER designated partner for pandemic vaccines by the German government</p> 	<p>EMPLOYEES 1,527 (As of Dec. 2025)</p> 	<p>COMPLIANCE-PROVEN QUALITY validated globally (EMA, FDA, ANVISA, MHRA, MFDS, etc.)</p> 

A Trusted Partner in Shaping a Healthier World



<p>VACCINES Leveraging decades of expertise, we specialize in creating innovative solutions to combat infectious diseases</p> 	<p>GENE & IMMUNE THERAPEUTICS The sole manufacturer of the first commercial oncolytic virus product approved by FDA & EMA</p> 	<p>STERILE FILL AND FINISH State-of-the-art aseptic filling technologies to handle liquid and lyophilized products</p> 
--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

End-to-End Services




Glocalization : Global+Localization

Expansion of production sites to align with local demand and conditions, positioning SK bioscience as a network of global vaccine hubs



Next Pandemic Preparedness

Collaboration with governments and global initiatives for the independent development of products and improvement of manufacturing capacity as needed for future pandemic preparedness



Partnership

Leveraging globally recognized technology, we collaborate with leading pharmaceutical companies and institutions worldwide on joint development and technology partnerships





	ESG strategy direction	ESG targets	Milestones (~2025)	Short-term targets (2026~2027)	Mid- and long-term targets (~2031)
E	Eco-friendly management system	• Climate change response and net zero	<ul style="list-style-type: none"> • Creation of a roadmap for GHG reduction • Issue of TCFD¹⁾ reports • PPAs for RE100 compliance 	• Advancement and disclosure of net zero roadmap	• Achievement of RE100 and net zero
		• Advanced environmental management system	<ul style="list-style-type: none"> • Adoption of company-wide environmental management policy • ISO 14001 certification • Carbon Disclosure Project (CDP) compliance 	<ul style="list-style-type: none"> • Biodiversity protection activities • Alignment with TNFD²⁾ • Advancement of environmental management performance systems 	<ul style="list-style-type: none"> • Improvement of environmental pollutant management • Review of environmental risks and opportunities during investment evaluation
S	Happiness of stakeholders	• Greater capacity and happiness of employees	<ul style="list-style-type: none"> • Strategic recruitment of talent and fostering of experts • Transparency in business human rights policy • Systematic assessment and audit of human rights 	<ul style="list-style-type: none"> • Adoption of an employee happiness program • Improvement of human rights assessment followed by necessary changes 	• DE&I as company culture
		• Social value in local communities	<ul style="list-style-type: none"> • Social responsibility strategies and long-term execution planning • Increase in philanthropic activities and performance management 	• Increased employee participation in goodwill activities and greater satisfaction	<ul style="list-style-type: none"> • Improved communication with local communities • Analysis and management of community-related risks
	Creation of social value across the industry	• Global biotech ecosystem	<ul style="list-style-type: none"> • Development of biotech professionals in Korea • Inauguration of the IVI-SK bioscience Park Mahnhoon Award • Vaccine fund investment 	<ul style="list-style-type: none"> • R&D project support • Biotech venture support 	<ul style="list-style-type: none"> • Open lab opportunities at the Global R&PD Center • Development of global vaccine experts
• Social value through business		<ul style="list-style-type: none"> • Disclosure of plans for emerging and developing markets • Training of healthcare professionals 	<ul style="list-style-type: none"> • Public health support for developing countries • Expansion of vaccine access through international procurement 	• Ensuring the affordability and accessibility of pharmaceuticals	
• Supply chain sustainability		<ul style="list-style-type: none"> • Adoption and implementation of a Code of Conduct for suppliers • ESG risk management of main suppliers 	• Strengthening ESG management across suppliers	<ul style="list-style-type: none"> • Partnered growth with suppliers • Participation in global supply chain management initiatives 	
G	Sustainable and transparent governance	• Board-driven management	<ul style="list-style-type: none"> • Establishment and operation of a new ESG committee • Enactment of the Charter of Governance • Systematic performance evaluation of the board of directors 	• Company-wide risk management and improved regulation of the board of directors	• Increased autonomy and diversity of the board of directors
		• Internalization of ESG management	<ul style="list-style-type: none"> • Setting and disclosure of ESG management strategies • Support and participation in ESG initiatives • Expansion of ESG application to the executive team's KPIs 	• Advancement of internalization initiatives for employees	<ul style="list-style-type: none"> • Expansion of ESG application to the relevant departments' KPIs • Further internalization by employees

1) Task Force on Climate-related Financial Disclosures
 2) Taskforce on Nature-related Financial Disclosures



Publisher_ SK bioscience

www.skbioscience.co.kr

82-32-209-5000

SK bioscience, 38, Yeongudanji-ro, Yeonsu-gu, Incheon, Republic of Korea

Copyright © SK bioscience. All Rights Reserved

SKB-PO06-202603-01